EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight

Niki Jalava iD, Terhi J Heino iD, Pirjo Nuutila iD, Kirsi A Virtanen iD, Kaisa K Ivaska iD

Clinical Endocrinology · 2026-02 · 104 (2) · 130-138

DOI: 10.1111/cen.70059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 24.11.2025. Verfasst von Niki Jalava und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland. Hauptthemen laut MEDLINE: Glucose, Bone and Bones, Body Weight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was supported by grants from the Research Council of Finland (grant# 325498 to K.K.I., #335446 to K.A.V.), Finnish Diabetes Research Foundation (K.A….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Bone is a target for diabetic complications, but the impact of metabolic changes on bone metabolism is less understood. Bones participate in energy metabolism by via secreted osteokines. Glucose ingestion reduces bone resorption, but the effects on osteokines remain unknown. Further, it is not known whether the response is altered in obesity. The objective of the study was to compare responses in circulating levels of osteokines to glucose ingestion between participants with normal weight (BMI < 26 kg/m 2 , n = 22) and obesity (BMI > 28 kg/m 2 , n = 27) (age = 21–54 yr).

Measurements

C‐terminal telopeptide of collagen I (b‐CTX‐I), total osteocalcin (OC), sclerostin, fibroblast growth‐factor 23 (cFGF23), uncarboxylated OC, and lipocalin 2 (LCN2) at baseline and after 2 h oral glucose tolerance test (OGTT).

Results

OGTT resulted in a significant decrease in bone resorption, median decrease in b‐CTX‐I was 42% ( p < 0.0001) in both groups. Osteokine levels were modestly but statistically significantly decreased, OC decreased by 11% ( p < 0.0001) and FGF23 by 14% ( p = 0.007) in both groups, while uncarboxylated OC decreased by 1.2% ( p < 0.0001) and sclerostin by 7.8% ( p = 0.032) only in participants with obesity. Although the differences in responses between the groups were not statistically significant, we observed a tendency for less pronounced effect on b‐CTX‐I ( p = 0.052) and a greater effect on OC ( p = 0.051) in participants with obesity compared to normal weight.

Conclusion

Osteokines respond rapidly to oral glucose regardless of body weight. Orally‐administered glucose affects not only bone turnover but can also suppress bone endocrine functions. Furthermore, obesity may influence the effect of oral glucose on circulating levels of bone turnover markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucoseBone and BonesBody WeightHumansMaleFemaleAdultMiddle AgedOsteocalcinFibroblast Growth Factor-23Glucose Tolerance TestObesityFibroblast Growth FactorsYoung AdultAdministration, OralCollagen Type IBone Morphogenetic ProteinsBone ResorptionAdaptor Proteins, Signal TransducingPeptides

Stichwörter der Autor:innen

bonebone endocrine functionsobesityoral glucose tolerance testosteokine

Substanzen

GlucoseOsteocalcinFibroblast Growth Factor-23Fibroblast Growth FactorsSOST protein, humanFGF23 protein, humancollagen type I trimeric cross-linked peptideCollagen Type IBone Morphogenetic ProteinsAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Institute of Biomedicine, University of Turku, Turku, Southwest Finland, Finland.
  • Turku PET Centre, University of Turku, Turku, Southwest Finland, Finland.
  • Turku PET Centre, Turku University Hospital, Turku, Southwest Finland, Finland.

ORCID-Profile: Niki Jalava, Terhi J Heino, Pirjo Nuutila, Kirsi A Virtanen, Kaisa K Ivaska

Förderung

  • This study was supported by grants from the Research Council of Finland (grant# 325498 to K.K.I., #335446 to K.A.V.), Finnish Diabetes Research Foundation (K.A…

Zitieren

APA

Jalava, N., Heino, T. J., Nuutila, P., Virtanen, K. A., & Ivaska, K. K. (2026). Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Clinical Endocrinology, 104(2), 130-138. https://doi.org/10.1111/cen.70059

Vancouver

Jalava N, Heino TJ, Nuutila P, Virtanen KA, Ivaska KK. Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight. Clinical Endocrinology. 2026;104(2):130-138. doi:10.1111/cen.70059

BibTeX
@article{Jalava2026,
  author = {Jalava, Niki and Heino, Terhi J and Nuutila, Pirjo and Virtanen, Kirsi A and Ivaska, Kaisa K},
  title = {Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight},
  journal = {Clinical Endocrinology},
  year = {2026},
  volume = {104},
  number = {2},
  pages = {130--138},
  doi = {10.1111/cen.70059}
}
Kostenlos starten →